Healthcare policy changes under the Trump administration have raised significant concerns regarding the future of medical research. Notable cuts have been made to research grants, and alterations to the CDC's vaccine advisory panel have been implemented. NIH employees have voiced strong opposition to these changes, outlining detrimental effects on research and funding. They indicate that these reductions will particularly impact research on rare cancers and infectious diseases. The financial burden is expected to shift towards big pharmaceutical companies, which will have to support early research and development previously funded by federal sources.
The Trump administration's healthcare policy changes have sparked a great deal of concern about their short and long-term consequences, especially regarding medical research funding.
NIH workers criticized recent cuts, stating they lead to a 'dramatic reduction in life-saving research,' affecting grants crucial for scientific progress.
The decision to change CDC vaccine advisory panel members to those with anti-vaccine stances has raised significant concerns about public health and safety.
Cuts to medical grants will likely shift the burden to big pharmaceutical companies, which will have to cover early R&D that was previously funded by the government.
Collection
[
|
...
]